Stay Informed. Stay Competitive. Get Free Email Updates Dow 30 & Emerging Growth

Stay Informed. Stay Competitive.

Get Free Updates

Dow 30 & Emerging Growth

J&J Janssen Unit Begins Mid-Stage COVID-19 Vaccine Trials In Spain

By John F. Heerdink, Jr.

Reportedly, Johnson & Johnson’s (JNJ) Janssen unit began mid-stage trials of its COVID-19 vaccine in Spain on 14th September 2020. 190 people are reported to take part in the country’s trials, which will take place in three hospitals and will be concluded by Sept. 22.

Phase II trials are being carried out in three countries, including the Netherlands and Germany apart from Spain. The trials in these three countries are expected to last two months and will include 550 participants in total.

Dow 30 component Johnson & Johnson (JNJ) is a worldwide healthcare focused company that embraces research and science so that it can provide customers with innovative ideas, products, and services. To learn more about Johnson & Johnson (JNJ) and to continue to track its progress visit the Vista Partners Johnson & Johnson Coverage Page.

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive! Please join us at Vista Partners and receive our FREE email updates throughout the week and view our exclusive content and research.

Post View Count : 161
(Read Original Story: J&J unit to start mid-stage COVID-19 vaccine trials in Spain in Reuters)


Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us